Research progress in acetyl-CoA carboxylase inhibitors
10.11665/j.issn.1000-5048.20190301
- VernacularTitle:乙酰辅酶A羧化酶抑制剂的研究进展
- Author:
Liankuo MEI
1
;
Qiangqiang WEI
;
Huibin ZHANG
;
Jinpei ZHOU
Author Information
1. 中国药科大学新药研究中心
- Publication Type:Journal Article
- Keywords:
acetyl-CoA carboxylase;
acetyl-CoA carboxylase inhibitors;
non-alcoholic fatty liver disease;
tumor;
progress
- From:
Journal of China Pharmaceutical University
2019;50(3):253-264
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease(NAFLD)is characterized by excessive fat deposition in hepatocytes, fat accumulates mainly in the form of triglycerides, triglycerides derive from esterification of glycerol and free fatty acids; and the synthesis of fatty acid is abnormally active in tumor cells, which is significantly higher than that of normal cells, providing necessary lipid substrates for the formation of biofilms, the production of signaling molecules and energy during the proliferation and development of tumor cells. Acetyl-CoA carboxylase(ACC)is the limiting-rate enzyme of de novo lipogenesis. And it is also an enzyme that catalyzes the first step of the fatty acid synthesis pathway; its catalyzed product, malonyl-CoA, also inhibits the oxidation of fatty acids. ACC inhibition can reduce fatty acid synthesis and promote fatty acid oxidation, which reduce the amount of fatty acids in the body. Hence, attenuating fat accumulation could improve NAFLD, and reduction of fatty acid content inhibits development of tumor tissues because lipid substrates could not satisfy the requirement of cancer cells. Therefore, ACC inhibitors have potential to be the novel drugs that can treat NAFLD and cancer. The recent research progress on ACC inhibitors is reviewed in this paper.
